Valbiotis Announces Positive Results from Cardio-Liver Study

Valbiotis, a French laboratory, has unveiled promising results from its Cardio-Liver clinical study. The study showed positive impacts on metabolic parameters, notably reducing liver fat. This development completes the clinical program for the Steadrive® active substance and paves the way for the commercial launch of ValbiotisPRO® Foie on September 23 in France, accessible via pharmacies and online.

The Cardio-Liver study was a randomized, placebo-controlled trial involving 71 participants with hepatic steatosis. Those receiving Steadrive® showed significant liver fat reduction. These findings will be shared at an upcoming international congress, reinforcing prior data on Steadrive®.

ValbiotisPRO® Foie aims to address liver health issues linked to metabolic imbalances, prevalent in about half of the French adult population. It utilizes a plant-derived formulation with over 10 years of research backing.